Blog, News

Summary of the $8.3 billion package to fund a response to coronavirus

besler insights blog corner graphic

Winning Strategies Washington

The following is a summary by Winning Strategies Washington on the $8.3 billion package to fund a response to coronavirus.

It provides $8.3 billion in all new funding for a robust response to this public health emergency. That includes $950 million for state and local health agencies to conduct vital public health activities, including surveillance, laboratory testing, infection control, contact tracing, and mitigation.

The following is a summary of its major provisions:

  • $61 million to the FDA to facilitate the development of medical countermeasures, devices, therapies, and vaccines to combat the coronavirus.
  • Allows $1 billion in loan subsidies to be made available to help small businesses, small agricultural cooperatives, small aquaculture producers, and non- profit organizations which have been impacted by financial losses as a result of the coronavirus outbreak.
  • $950 million for the CDC, of which $475 million must be allocated within 30 days, to support States, locals, territories, and tribes to conduct public health activities.
  • $300 million to replenish the Infectious Diseases Rapid Response Reserve Fund, which supports immediate response activities during outbreaks.
  • Allows funding for CDC’s repatriation and quarantine efforts, laboratory testing, emergency operations, epidemiological investigations, public information, and surveillance and data analysis.
  • Allows reimbursement for State or local costs incurred for coronavirus preparedness and response activities between January 20 and the date of enactment of this emergency supplemental.
  • Allows funds to be used for construction or renovation of facilities to improve preparedness and response capabilities at the State and local level.
  • More than $2 billion for the Biomedical Advanced Research and Development Authority (BARDA) to support advanced research and development of vaccines, therapeutics, and diagnostics, prioritizing platform-based technologies with U.S.-based manufacturing.
  • $826 million for the National Institutes of Health to support basic research and development of vaccines, therapeutics, and diagnostics.
  • $300 million in contingency funding for procurement of vaccines, therapeutics, and diagnostics.
  • Requires that vaccines, therapeutics, and diagnostics developed using taxpayer funds must be available for purchase by the Federal government at a fair and reasonable price. Allows the Secretary of Health and Human Services to ensure that vaccines, therapeutics, and diagnostics developed using taxpayer funds be affordable in the commercial market.

SUBSCRIBE for Weekly Insider Updates

  • Podcast Alerts
  • Healthcare Finance News
  • Upcoming Webinars

By submitting your email address, you are agreeing to receive email communications from BESLER.

BESLER respects your privacy and will never sell or distribute your contact information as detailed in our Privacy Policy.

New Webinar

Wednesday, December 14, 2022
1 PM ET

live streaming
Podcasts
Insights

Partner with BESLER for Proven Solutions.

whiteboard